Stock events for PAVmed, Inc. (PAVM)
In February 2026, PAVmed closed preferred stock and senior secured note financings, eliminating all previously outstanding convertible securities. In January 2026, Lucid Diagnostics was awarded a U.S. Department of Veterans Affairs contract for EsoGuard®, leading to a surge in PAVmed's stock price. In December 2025, PAVmed announced a 1-for-30 reverse stock split, and Lucid Diagnostics announced positive data from esophageal precancer detection. In November 2025, PAVmed reported its third-quarter 2025 financial results, which included a GAAP net loss of $6 million and a non-GAAP loss of $446,000, leading to a negative stock reaction. Between March 3, 2025, and February 27, 2026, PAVM's share price declined by 51.37%, but increased by 42.2% between the beginning of 2026 and March 6, 2026. The company reported a significant 513% revenue jump in Q2 2025, and Lucid Diagnostics is approaching a crucial Medicare coverage milestone for EsoGuard.
Demand Seasonality affecting PAVmed, Inc.’s stock price
There is no specific information detailing demand seasonality for PAVmed's products and services. Diagnostic screening for serious conditions is generally considered a critical, non-discretionary medical need, which may imply less susceptibility to seasonal fluctuations in demand compared to elective procedures. The available information primarily discusses the seasonality of PAVmed's stock price, indicating that March may not be an ideal month for investment while April historically shows a higher probability of positive returns for the stock.
Overview of PAVmed, Inc.’s business
PAVmed, Inc. is a diversified, commercial-stage medical technology company operating across the medical device, diagnostics, and digital health sectors, primarily in the surgical and medical instrument manufacturing industry. The company advances medical technologies from concept to commercialization through multiple business lines and subsidiaries. Its diagnostics division, through Lucid Diagnostics, focuses on cancer prevention and early detection, particularly for esophageal precancer, with products like EsoGuard® and EsoCheck®. PAVmed develops and commercializes medical devices such as CarpX, EsoCure, and PortIO. Through Veris Health Inc., PAVmed focuses on digital cancer care and remote patient monitoring via the Veris Cancer Care Platform. PAVmed operates with a shared services model, supporting its independently financed subsidiaries.
PAVM’s Geographic footprint
PAVmed Inc. is headquartered in New York City, New York, and has operations across the U.S. Its sales and marketing activities extend into international markets.
PAVM Corporate Image Assessment
Information specifically detailing PAVmed Inc.'s overall brand reputation is limited. However, its subsidiary, Lucid Diagnostics, was named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree in November 2025. The company's public communications highlight its status as a commercial-stage medical technology company focused on innovation and improving patient care.
Ownership
Insiders hold 50.74% of PAVmed Inc.'s shares, with Ira Scott Greenspan being the largest individual shareholder at 24.09%. Retail investors hold 44.31% of the shares. Major institutional owners include Captrust Financial Advisors, SBI Securities Co., Ltd., AdvisorNet Financial, Inc., First Manhattan CO. LLC., Geode Capital Management LLC, Jane Street Group LLC, The Vanguard Group, Inc., and BlackRock, Inc. As of March 4, 2026, institutional investors held a total of 65,160 shares.
